CLAIMS

1. A pharmaceutical combination for use in the treatment of a type 2 diabetes mellitus patient, said combination comprising
   (a) a pharmaceutical formulation comprising
      (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, and
      (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof,
   (b) an SGLT2 inhibitor, or/and a pharmaceutically acceptable salt thereof, and
   (c) metformin or/and pharmaceutically acceptable salt thereof.

   wherein the type 2 diabetes mellitus to be treated is not adequately controlled with
   (i) the SGLT2 inhibitor alone;
   (ii) an SGLT2 inhibitor and an oral anti-diabetic alone;
   (iii) the SGLT2 inhibitor and metformin alone, or with an SGLT2 inhibitor and a GLP-1 receptor agonist alone; and/or
   (iv) the SGLT2 inhibitor, metformin and a GLP-1 receptor agonist alone

2. The pharmaceutical combination for use according to claim 1, wherein the SGLT2 inhibitor is selected from the group consisting of empagliflozin, canagliflozin, dapagliflozin and ertugliflozin.

3. The pharmaceutical combination for use according to any one of the preceding claims, wherein the pharmaceutical formulation (a) comprises insulin glargine in a concentration of 100 to 500 U/mL.

4. The pharmaceutical combination for use according to any one of the preceding claims, wherein the pharmaceutical formulation (a) comprises insulin glargine in a concentration of 100 U/mL.

5. The pharmaceutical combination for use according to any one of the

preceding claims, wherein the pharmaceutical formulation (a) comprises lixisenatide in a concentration of 20 to 150 µg/ml.

6. The pharmaceutical combination for use according to any one of the preceding claims, wherein the pharmaceutical formulation (a) comprises lixisenatide in a concentration of 33 µg/mL, 50 µg/mL or 100 µg/mL.

7. The pharmaceutical combination for use according to any one of the preceding claims, wherein the pharmaceutical formulation (a) comprises insulin glargine in a concentration of 100 U/ml, and lixisenatide in a concentration of 33 µg/mL, 50 µg/mL or 100 µg/mL.

8. The pharmaceutical combination for use according to any one of the preceding claims, wherein the GLP-1 receptor agonist is selected from lixisenatide, exenatide, dulaglutide, and liraglutide.

9. The pharmaceutical combination for use according to any one of the preceding claims, wherein the patient to be treated is obese.